Anticonvulsant testing with a new analeptic convulsant: N-sulfamoyl-hexahydro-azepine (Sah 41-178).
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001381:Azepines / Q000037:antagonists & inhibitors*; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors*; D002707:Chlordiazepoxide / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003975:Diazepam / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004597:Electroshock; D005984:Glutethimide / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D013331:Strychnine / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000037:antagonists & inhibitors*; D014293:Trimethadione / Q000494:pharmacology
D000081:Acetamides; D000927:Anticonvulsants; D001381:Azepines; D000697:Central Nervous System Stimulants; D013449:Sulfonamides; D010672:Phenytoin; D002707:Chlordiazepoxide; D005984:Glutethimide; D013331:Strychnine; D006220:Haloperidol; D003975:Diazepam; D014293:Trimethadione; D002746:Chlorpromazine; D010433:Pentylenetetrazole; D010634:Phenobarbital